| Ref (type) | Population | Outcome, Interventions | Results and statistical analysis | Effect size | Favours |
| Symptom improvement | |||||
|
RCT |
30 men In review |
Physician-rated improvement
3 months
7/10 (70%) with pentosan polysulfate sodium 200 mg twice daily 5/14 (36%) with placebo |
RR 2.00 95% CI 0.87 to 4.40 The RCT may have been too small to detect important clinical differences between groups |
Not significant | |
|
RCT |
30 men In review |
Proportion of people reporting improvement in symptom score
3 months
5/10 (50%) with pentosan polysulfate sodium 200 mg twice daily 6/14 (43%) with placebo |
RR 1.2 95% CI 0.5 to 2.8 |
Not significant | |
|
RCT |
100 men |
Mean score improvement in the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) total score
16 weeks
5.9 with pentosan polysulfate 300 mg three times daily 3.2 with placebo |
P = 0.081 |
Not significant | |
|
RCT |
100 men |
Mean score improvement in the NIH-CPSI score for urinary symptoms domain
16 weeks
1.2 with pentosan polysulfate 300 mg three times daily 0.5 with placebo |
P = 0.374 |
Not significant | |
|
RCT |
100 men |
Mean score improvement in the NIH-CPSI score for pain domain
16 weeks
2.7 with pentosan polysulfate 300 mg three times daily 1.7 with placebo |
P = 0.21 |
Not significant |